<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>10 Pancreatic tumours</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part15.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part17.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark15" class="s95" name="bookmark51">Chapter 10</a><a name="bookmark52">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_155.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark15" class="h2">Pancreatic </a><h2 href="#bookmark15">tumours</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">David Bowden and Thankamma ajithkumar</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Approximately 9400 new cases of pancreatic cancer are diagnosed in the UK and 367,000 new cases globally every year. The peak incidence is in the 65–75-year age group, with 60% of patients being older than 65 years of age. Approximately 10–15% patients present with early stage disease amenable to curative surgery, 30–40% with locally advanced inoperable disease, and the remainder with metastatic disease. The overall five-year survival is less than 5%.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Common symptoms at presentation are painless jaundice, epigastric pain radi- ating to the back, and unexplained weight loss. Radical resection (typically with a pancreatico-duodenectomy: Whipple’s procedure) with a negative margin (R0) is the only curative treatment but is associated with a 1–5% mortality and 20% mor- bidity; however, R0 resection is only feasible in 40–60% patients with localized disease. After R0 resection the median survival is 24 months, which falls to 18 months with a margin-positive resection. Accurate imaging is important in optimal therapeutic de- cision making, especially in order to identify tumours in which an R0 resection is potentially achievable.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2 <span class="h4">Diagnosis and staging</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2.1 <span class="s29">Diagnosis</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2.1.1 <span class="s98">Transabdominal ultrasound</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Transabdominal ultrasound (TAUS) is often the initial examination in patients with painless jaundice. It can detect biliary and/or pancreatic duct dilatation (double duct sign), larger tumours &gt;2 cm, and liver metastases. Image quality is, however, signifi- cantly affected by multiple factors, including operator expertise, patient body habitus, and the presence of overlying bowel gas. As a result, sensitivity may be as low as 75%, making it an unsuitable imaging modality for the surveillance of individuals at high risk of malignancy.<span class="s22">1</span></p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2.1.2 <span class="s98">Computed tomography</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Triple-phase computed tomography (CT) is the investigation of choice for diagnosis and staging. A typical scanning protocol will use 1000 mL oral water as negative</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="181" alt="image" src="Image_156.jpg"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 10.1 <span class="s52">axial contrast-enhanced CT image showing a hypoenhancing mass arising within the head of the pancreas (arrow). note dilatation of the intrahepatic ducts secondary to biliary obstruction (dilated ducts near the asterisk).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">intraluminal contrast with 100–150 mL intravenous iodinated contrast injected at 4 mL/s via a power injector. Thin (1–2 mm) slices are obtained in both a pancreatic par- enchymal phase (approximately 40 s or using bolus tracking) and a later portal venous phase (70 s). The main aim is to maximize the attenuation difference between the tu- mour and normal pancreas. Approximately 90% of tumours will be hypo-enhancing relative to normal pancreatic parenchyma (Figure 10.1). The late arterial pancreatic phase also allows more accurate detection of vascular involvement. An early arterial phase (at approximately 20 s) can subsequently be acquired if additional surgical plan- ning of vascular anatomy is required, thereby facilitating the generation of multiplanar and 3D (volume rendered) images with post-processing tools. Accuracy of CT in detecting pancreatic adenocarcinoma is 85–100%.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A well-recognized sign of an obstructing pancreatic tumour is the classical ‘double duct’ sign in which both the common bile and pancreatic ducts are obstructed with resultant upstream dilatation. In cases where the primary lesion cannot be seen, more subtle secondary signs are useful (Table 10.1). If the primary lesion cannot be identified</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 10.1 <span class="s52">secondary signs of a pancreatic tumour</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_157.png"/></span></p><p class="s39" style="padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Sign               Remark</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_158.png"/></span></p><p class="s54" style="padding-top: 1pt;padding-bottom: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">pancreatic duct cut-off      subtle sign</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_159.png"/></span></p><p class="s54" style="padding-top: 1pt;padding-bottom: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">upstream pancreatic atrophy    subtle sign</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_160.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_161.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_162.png"/></span></p><p class="s54" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 161%;text-align: left;">Vascular occlusion       look for development of collateral vessels loss of normal pancreatic margins   use gastroduodenal artery as a landmark</p><p class="s54" style="padding-bottom: 2pt;padding-left: 144pt;text-indent: -138pt;line-height: 111%;text-align: left;">Double duct sign        always abnormal but can also be seen in chronic pancreatitis as a result of benign strictures</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_163.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="125" alt="image" src="Image_164.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 10.2 <span class="s52">axial CT image (a) showing dilatation of the pancreatic duct with an abrupt cut-off of a dilated pancreatic duct (arrow), but no visible tumour; eus (b) clearly demonstrates an obstructing tumour, marked with calipers.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">with CT, in the presence of these secondary signs, further evaluation with endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) is indicated (Figure 10.2).</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2.1.3 <span class="s98">Endoscopic ultrasound</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A pancreatic cancer will typically appear as an irregular hypoechoic mass relative to the normal pancreatic tissue. Its accuracy rates for diagnosing tumours are higher than multidetector CT (MDCT) (97%), particularly for tumours &lt;2 cm in size. A normal EUS can reliably exclude a tumour with a negative predictive value approaching 100%. In a majority of patients EUS-guided fine needle biopsy is the method of choice for histological diagnosis and carries a lower risk of peritoneal seeding compared to other percutaneous approaches. EUS-guided coeliac axis nerve block can be also be useful in the palliative setting.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2.1.4 <span class="s98">Magnetic resonance imaging</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">MRI, in particular the use of magnetic resonance cholangiopancreatography (MRCP), has an established role for evaluating biliary tree pathology, but is less commonly used to diagnose pancreatic cancer. However, it may be useful where sec- ondary signs are present but the primary lesion is not seen at CT. The ‘duct penetra- tion sign’, in which a dilated pancreatic duct is seen to traverse a stricture or possible mass without complete obstruction, can be useful to differentiate between chronic pancreatitis and adenocarcinoma. Studies have demonstrated diagnostic accuracies of 76–89%. Unenhanced fat-saturated T1-weighted imaging is also of particular use in the evaluation of pancreatic parenchyma, given its innate hyperintensity as a result of abundant endoplasmic reticulum, high manganese, and protein content. Tumours typically are therefore visible as a focus of hypo-intensity relative to back- ground parenchyma.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">10.2.1.5 <span class="s98">Endoscopic retrograde cholangiopancreatography</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Endoscopic retrograde cholangiopancreatography (ERCP) is often performed to palliate obstruction to the biliary tract by stenting. However, the presence of stents in the common bile duct and any post-procedural inflammation can hinder inter- pretation of subsequent staging imaging and ideally these should be performed prior to ERCP.</p><p class="s97" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.2.1.6 <span class="s98">F-fluorodeoxyglucose positron emission tomography/CT</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">F-fluorodeoxyglucose positron emission tomography/CT (<span class="s113">18</span>FDG PET/CT) in routine staging of pancreatic cancer has not been defined. However, it may be considered for patients with equivocal para-aortic nodal or other disease, but otherwise resectable disease.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.2.2 <span class="s29">Staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This is performed to assess for potential resectability of the primary tumour (locoregional stage) and to identify distant metastases (commonly peritoneum, liver, and lungs). The accepted standard for staging of pancreatic cancers is based on the TNM (tumour, node, metastasis) staging system.<span class="s22">2</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">10.3 <span class="h4">Therapeutic staging classification</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Localized pancreatic cancers are classified into resectable, borderline resectable, and locally advanced disease.<span class="s22">3 </span>Patients with resectable disease proceed with primary sur- gery followed by adjuvant chemotherapy, whereas those with borderline-resectable and locally advanced tumours are considered for neoadjuvant treatment, usually with combination chemotherapy (Figure 10.3). Patients who continue to be inoperable after neoadjuvant chemotherapy may be considered for radical chemo-radiotherapy.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There are a number of criteria for classification of localized tumours (e.g. MD Anderson, NCCN, etc.). The 2017 International consensus on criteria for classification of localized tumours are given in Table 10.2</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: right;">The accuracy of MDCT in staging and resectability ranges from 85% to 95%, with an accuracy up to 90% for the exclusion of unresectable disease. Since pancreatic cancer tends to spread early via the lymphatics, it is important to try to recognize subtle in- volvement of the peripancreatic tissue, as well as early peritoneal or perineural spread. Distant metastases in pancreatic cancer commonly occur in the liver, peritoneum, and lungs. Liver metastases generally appear as low attenuation, ill-defined lesions on CT and are typically solid on US. The presence of ascites is often a sign of peritoneal</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="404" height="140" alt="image" src="Image_165.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 10.3 <span class="s52">axial CT image (a) demonstrating ‘tear-drop-like’ distortion of the sMV secondary to encasement by an adjacent tumour within the pancreatic head. axial CT image (b) in a separate patient shows subtle early involvement of the sMa (with calcified wall) by tumour extension from an uncinate process mass.</span></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 10.2 <span class="s52">international consensus on classification of localized tumours</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:14pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Criteria</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Resectable</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Borderline</p></td><td style="width:78pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Locally</p></td></tr><tr style="height:12pt"><td style="width:70pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Borderline-PV</p></td><td style="width:78pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Borderline-A</p></td><td style="width:62pt"><p class="s26" style="text-indent: 0pt;line-height: 7pt;text-align: left;">advanced</p></td></tr><tr style="height:13pt"><td style="width:70pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">(arterial)</p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Venous</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">no tumour</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Tumour contact</p></td><td style="width:78pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">—</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Bilateral</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">involvement:</p></td><td style="width:51pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">contact or</p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">180° or greater</p></td><td style="width:78pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">narrowing/</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">superior mesenteric</p></td><td style="width:51pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">unilateral</p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">or bilateral</p></td><td style="width:78pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">occlusion,</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">vein (sMV)/portal</p></td><td style="width:51pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">narrowing</p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">narrowing/</p></td><td style="width:78pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">exceeding the</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">vein (pV)</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">occlusion, not</p></td><td style="width:78pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">inferior border of</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">exceeding the</p></td><td style="width:78pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">the duodenum</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">inferior border of</p></td><td style="width:78pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:70pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="text-indent: 0pt;text-align: left;">the duodenum</p></td><td style="width:78pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:70pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">arterial</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">no tumour</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">no tumour</p></td><td style="width:78pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sMa, Ca: tumour</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sMa, Ca: tumour</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">involvement:</p></td><td style="width:51pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">contact</p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">contact/invasion</p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">contact of</p></td><td style="width:62pt"><p class="s99" style="padding-right: 1pt;text-indent: 0pt;line-height: 9pt;text-align: right;">contact/invasion</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">superior mesenteric</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">less than 180°</p></td><td style="width:62pt"><p class="s99" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of 180° or</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">artery (sMa),</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">without showing</p></td><td style="width:62pt"><p class="s99" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">more degree</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">coeliac axis (Ca),</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">deformity/stenosis</p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">Cha: tumour</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">common hepatic</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Cha: tumour</p></td><td style="width:62pt"><p class="s99" style="padding-right: 1pt;text-indent: 0pt;line-height: 9pt;text-align: right;">contact/invasion</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">artery (Cha)</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">contact without</p></td><td style="width:62pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: right;">showing tumour</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">showing tumour</p></td><td style="width:62pt"><p class="s99" style="padding-right: 1pt;text-indent: 0pt;line-height: 9pt;text-align: right;">contact/invasion</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">contact of the</p></td><td style="width:62pt"><p class="s99" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of the proper</p></td></tr><tr style="height:11pt"><td style="width:70pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pha and/or Ca</p></td><td style="width:62pt"><p class="s99" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hepatic artery</p></td></tr><tr style="height:13pt"><td style="width:70pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:78pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">and/or Ca</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 109%;text-align: left;">source: data from isaji s, et al. ‘international consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017’. <i>Pancreatology. </i>Jan 2018, Vol. 18, issue 1, pp. 2–11.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">spread. Small tumour deposits on the peritoneum and liver surface will be subtle on imaging and require a high index of suspicion, although modern thin-section CT has improved sensitivity for their detection. If imaging findings continue to be non- specific, staging laparoscopy is useful prior to definitive resection.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">10.4 <span class="h4">Mucinous neoplasms of the pancreas</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">With the widespread use of CT and MRI in modern imaging, incidental cystic lesions within the pancreas are being detected with relative frequency. These are classified as mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasm (IPMNs).<span class="s22">5,6 </span>Other benign cystic lesions include serous cystadenomas, pseudocysts, and epithelial cysts.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MCNs predominate in the body and tail of the pancreas occurring at a median age of 40–50 years, almost exclusively in women. They have an ovarian-type stroma secreting mucin and do not communicate with the pancreatic duct. The classic appearance of an MCN is of a unilocular or multilocular cystic lesion, each cyst &gt;2 cm in diameter, perhaps containing a solid or papillary nodule or exhibiting punctuate mural calcifi- cation. Serous cystadenomas, on the other hand, are usually located around the head, contain smaller cysts, and have an extremely low (but not non-existent) malignant potential.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="417" height="169" alt="image" src="Image_166.jpg"/></span></p><p class="s69" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(a)</p><p class="s69" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s69" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(a)</p><p class="s114" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(b)</p><p class="s114" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s114" style="text-indent: 0pt;line-height: 10pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 10.4 <span class="s52">Contrast-enhanced axial CT (a) shows marked pancreatic duct dilatation secondary to an intraductal papillary mucinous tumour (arrow). Coronal MrCp image</span></p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 119%;text-align: left;">(b) demonstrates diffuse dilatation of the entire main pancreatic duct (arrow). <span class="s115">images courtesy of Dr. ed godfrey, Cambridge university hospitals nhs Foundation Trust, Cambridge, uK.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">IPMNs are slow- growing tumours, subdivided into main duct and side branch duct types. Side-branch duct type is most commonly found in the pancreatic head, neck, and uncinate process, often appearing as a cystic lesion on imaging. Main duct type IPMN has the higher risk of developing malignancy (50% at five years) compared with side branch duct type (15% at years). Imaging appearances can often be very similar to those seen in chronic pancreatitis or other cystic lesions. Features suggestive of IPMN include location in the head and uncinate process, commu- nication with the main pancreatic duct, presence of solid components within the lesion, and bulging of the duodenal papilla due to mucin secretion (Figure 10.4). A study demonstrated accuracies for the diagnosis of IPMN of 76% for MDCT and 80% for MRCP.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Differentiation of MCN from the other cystic lesions is often not easy on CT, MRI, or US appearances alone. EUS, however, is able to aid in this differentiation by enabling EUS fine needle aspiration, and obtaining fluid from these cystic lesions. This can be analysed for cytological malignancy, amylase content, and carcinoembryonic antigen (CEA) levels. Using this approach, a study demonstrated 100% sensitivity and 89% specificity for differentiating benign from malignant lesions.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">10.5 <span class="h4">Imaging for radiotherapy planning</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">While external beam radiotherapy can be used in pancreatic cancer as a curative or palliative treatment, randomized trials have reported conflicting results regarding its benefit. In the postoperative setting, a meta-analysis and the RTOG 9704 trial did not show any benefit with adjuvant chemo-radiotherapy.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In patients with borderline tumour, ongoing studies are evaluating the role of con- ventional radiotherapy or stereotactic ablative body radiotherapy (SABR) in improving overall resection and margin-negative resection rates. In patients with locally advanced unresectable tumours, the LAP-07 study did not show any difference in median survival</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">between chemotherapy and chemo-radiotherapy (16.5 vs. 15.2 months, p = 0.83) after four months of chemotherapy.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">However, most guidelines recommend consideration for radical chemo-radiotherapy if there is at least stable localized disease after 3–4 months of chemotherapy.<span class="s22">7,8 </span>Alternatively, patients could be enrolled into clinical trials. Radical fractionated radio- therapy is often combined with synchronous fluoropyrimidine-based chemotherapy, such as oral capecitabine (chemoradiotherapy or CRT) as a radiosensitizer. A meta- analysis suggests that SABR (35–50 Gy in five fractions) is equally effective in locally advanced pancreatic cancer.<span class="s22">9</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Treating pancreatic cancers with radiotherapy is technically challenging. Target volume delineation is particularly challenging as there are uncertainties in defining the extent of tumour, especially identifying tumour spread along the splanchnic plexus and identifying lymph node involvement. For 3D radiotherapy planning, CT imaging with ≤3 mm slice thickness during free breathing is obtained with the patient appro- priately immobilized (supine position with arms above head).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For 4D planning, exhale breath-hold, contrast-enhanced, 3D-CT scan (CE-3DCT) using a pancreatic protocol followed by a 4D-CT is used. Intravenous contrast with or without opacification of the bowel will help to delineate the anatomy, particularly to distinguish bowel loops and vasculature from tumour and lymph nodes. Critical structures including the duodenum, liver, spinal cord, and both kidneys are outlined. The tumour and visible lymph nodes of &gt;1 cm in short axis (gross tumour volume— GTV) are then identified and outlined, often with the help of a cross-sectional radiolo- gist. The CTV margin is generally 5 mm.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For 3D planning, a 15 mm margin is added to CTV in superior-inferior directions and 10 mm circumferentially to obtain the PTV margin. This is to allow for micro- scopic spread of the tumour beyond CT resolution, organ movement, and daily vari- ation of patient positioning. The PTV margin for 4D planning is typically 3–5 mm. Taking into account the predefined dose constraints to the critical structures, a 3–4- field coplanar conformal or IMRT/VMAT plan is made and used to deliver radio- therapy (Figure 10.5). Conventional fractionated radiotherapy is given to a dose of</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">50.4 Gy in 28 fractions delivering five fractions daily with concurrent chemotherapy (usually capecitabine).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="104" alt="image" src="Image_167.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 10.5 <span class="s52">Contrast-enhancing planning CT scan (a) shows an ill-defined hypodense lesion in the head of the pancreas (thick arrow) which is involving superior mesenteric vessels (thin arrow). The lesion is located in the C-loop of the duodenum (b) and treated with iMrT (c) for optimal sparing of the duodenum and bowel.</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Palliative radiotherapy is given for pain relief or bleeding into the duodenum. Localization of the tumour should be performed using CT and treated with a 2–3 cm margin using parallel opposed anterior and posterior fields, 3D conformal radio- therapy using a 3–4-field plan or IMRT/VMAT. Painful bone and soft tissue metastatic disease can respond well to short courses of palliative radiotherapy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">10.6 <span class="h4">Therapeutic assessment and follow-up</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Follow-up of patients after surgical resection usually involves clinical assessment with or without tumour marker (CA19-9 and CEA) measurements. Further evalu- ation (usually with CT) is indicated if there is clinical suspicion of recurrent disease. Common sites of relapse include local and lymph node recurrence, peritoneal, liver, and lung metastases. The use of FDG PET/CT scanning may be useful to distinguish recurrent disease from postoperative changes.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For selected patients who have completed definitive CRT for locally advanced unresectable pancreatic cancer, a reassessment CT may be performed at 4–8 weeks to document treatment response and to exclude metastatic disease. Curative resection may be considered in a small proportion of these patients as salvage for treatment failure.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">10.6 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">◆ <span class="p">Ductal adenocarcinoma is the most common malignant pancreatic tumour and</span></p><p style="padding-left: 17pt;text-indent: 0pt;line-height: 12pt;text-align: left;">&gt;80% are unresectable at diagnosis.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">CT is performed for staging and to determine resectability.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">EUS is useful for detecting small cancers not visible on CT and for obtaining histo- logical confirmation of malignancy.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">There is no role for routine surveillance following curative treatment.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">1. <b>Ashida R</b>, <b>Tanaka S</b>, <b>Yamanaka H, et al. </b>(2018). The role of transabdominal ultrasound in the diagnosis of early stage pancreatic cancer: review and single-center experience. <i>Diagnostics </i>(Basel), <b>9</b>(1): ii: E2. doi: 10.3390/diagnostics9010002.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">2. <b>Sobin LH</b>, <b>Gospodarowicz MK</b>, <b>Wittekind CH (2017)</b>. <i>UICC TNM Classification of Malignant Tumours </i>(eighth edn). Oxford: Wiley Blackwell, p.93.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">3. <b>Ducreux M</b>, <b>Cuhna AS</b>, <b>Caramella C, et al. </b>(2015). ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i>, <b>26</b>(5): v56–68.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: justify;">4. <b>Isaji S</b>, <b>Mizuno S</b>, <b>Windsor JA, et al. </b>(2018). International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. <i>Pancreatology</i>, <b>18</b>(1): 2–11.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">5. <b>Lim J</b>, <b>Allen PJ </b>(2019). The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made? <i>Updates in Surgery</i>, <b>71</b>(2): 209–216.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">6. <b>Chandwani R</b>, <b>Allen PJ </b>(2016). Cystic neoplasms of the pancreas. <i>Annual Reviews in Medicine</i>, <b>67</b>: 45–57.</p><p class="s74" style="padding-top: 4pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">7. <b>O’Reilly D</b>, <b>Fou L</b>, <b>Hasler E, et al. </b>(2018). Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National Institute for Health and Care Excellence. <i>Pancreatology</i>, <b>18</b>(8): 962–970.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">8. <b>Balaban EP</b>, <b>Mangu PB</b>, <b>Yee NS </b>(2017). Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology and Practicals</i>, <b>13</b>(4): 265–269.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">9. <b>Petrelli F</b>, <b>Comito T</b>, <b>Ghidini A</b>, <b>Torri V</b>, <b>Scorsetti M</b>, <b>Barni S </b>(2017). Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. <i>International Journal of Radiation Oncology. Biology. Physics</i>, <b>97</b>(2): 313–322.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part15.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part17.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
